Delving into the Latest Updates on Lateral Pharma Pty Ltd. with Synapse

The study consists of two parts. Part A will evaluate the safety and tolerability of intravenous LAT8881 in healthy volunteers using an ascending dose schedule. Part B will evaluate the analgesic efficacy of a single intravenous dose of LAT8881, compared with placebo, in patients with lumbar radicular pain.
Healthy volunteers are not accepted for Part B.

开始日期2022-05-17

申办/合作机构

Lateral Pharma Pty Ltd.

[+1]

ACTRN12619001369112 / Completed临床2期

A proof of concept study of the efficacy and safety of oral LAT8881 in acute migraine

开始日期2019-10-04

申办/合作机构

Lateral Pharma Pty Ltd.

NCT04153409 / Completed临床2期

A Proof of Concept Study of the Efficacy and Safety of Oral LAT8881 in Acute Migraine

This is a randomised, placebo controlled, double blind, crossover proof of concept study to investigate the efficacy and safety of oral LAT8881 in acute migraine, with or without aura.

开始日期2019-09-24

申办/合作机构

Lateral Pharma Pty Ltd.

100 项与 Lateral Pharma Pty Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Lateral Pharma Pty Ltd. 相关的专利（医药）

登录后查看更多信息

1

项与 Lateral Pharma Pty Ltd. 相关的文献（医药）

2024-08-16·The Journal of Infectious Diseases

Harnessing Endogenous Peptide Compounds as Potential Therapeutics for Severe Influenza

Article

作者: Tate, Michelle D ; Ely, Lauren K ; Hodges, Christopher ; West, Alison C ; Harpur, Christopher M ; Lam, Maggie ; Le Page, Mélanie A ; Gearing, Andrew J

AbstractBackgroundExcessive pulmonary inflammation and damage are characteristic features of severe influenza virus infections. LAT8881 is a synthetic 16–amino acid cyclic peptide form of a naturally occurring C-terminal fragment of human growth hormone with therapeutic efficacy against influenza. Shorter linear peptides are typically easier to manufacture and formulate for delivery than larger cyclic peptides. A 6–amino acid linear peptide fragment of LAT8881, LAT9997, was investigated as a potential influenza therapy.MethodsLAT9997 was evaluated for its potential to limit disease in a preclinical mouse model of severe influenza infection.ResultsIntranasal treatment of mice with either LAT8881 or LAT9997 from day 1 following influenza infection significantly improved survival outcomes. Initiating LAT9997 treatment at the onset of severe disease also significantly improved disease severity. Greater disease resistance in LAT9997-treated mice correlated with reduced lung immunopathology, damage markers, vascular leak, and epithelial cell death. Treatment reduced viral loads, cytokines, and neutrophil infiltration in the airways yet maintained protective alveolar macrophages in a dose-dependent manner. Sequential trimming of N- and C-terminal amino acids from LAT9997 revealed a structure-activity relationship.ConclusionsThese findings provide preclinical evidence that therapeutic LAT9997 treatment limits viral burden and characteristic features of severe influenza, including hyperinflammation and lung damage.SummaryExcessive pulmonary inflammation and damage are characteristic features of severe influenza virus infections. LAT9997 is a linear peptide fragment derived from human growth hormone. This study provides preclinical evidence that therapeutic LAT9997 treatment limits viral burden, hyperinflammation, and lung damage.

100 项与 Lateral Pharma Pty Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Lateral Pharma Pty Ltd. 相关的转化医学

登录后查看更多信息